Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms. The diagnosis is based on histopathological and immunohistochemical analyses. The treatment is heterogeneous and includes several local and systemic therapeutic strategies. Methods: This is a retrospective cohort study including 86 KS patients treated between 1993 and 2022 at the University Hospital of Padua (AOPD) and at the Veneto Institute of Oncology (IOV). The data were extracted from an electronic database. Survival curves were generated using the Kaplan–Meier method, and Cox regression models were employed to explore associations with overall and disease-free survival. The male sex (89.53%), classical variant (43.02%), and cutaneous involvement (77.9%) were predominant. More than 61.6% of patients received a single treatment. Surgery, antiretroviral therapy, and chemotherapy were the mostly adopted approaches. A persistent response was observed in approximately 65% of patients, with a 22% relapse rate (at least 2 years). The overall survival ranges from 90 to 70% at 2 to 10 years after the diagnosis. Iatrogenic KS demonstrated a higher mortality (52.9%). This study reflects our experience in the management of KS. Comorbidities are very frequent, and treatments are heterogeneous. A multidisciplinary approach involving multiple referral specialists is essential for the appropriate management of this disease during diagnosis, treatment, and follow-up.
卡波西肉瘤（KS）是一种罕见的血管增生性肿瘤，根据临床流行病学特征可分为四种不同类型。其诊断主要基于组织病理学和免疫组织化学分析。治疗方案具有异质性，涵盖多种局部及全身性治疗策略。方法：本研究为回顾性队列研究，纳入1993年至2022年间在帕多瓦大学医院（AOPD）及威尼托肿瘤研究所（IOV）接受治疗的86例KS患者。数据来源于电子数据库。采用Kaplan-Meier法绘制生存曲线，并运用Cox回归模型分析总生存期和无病生存期的相关因素。结果显示男性患者（89.53%）、经典型（43.02%）及皮肤受累（77.9%）占主导地位。超过61.6%的患者接受单一治疗方案，其中手术、抗逆转录病毒治疗和化疗为主要治疗方式。约65%患者获得持续缓解，复发率为22%（至少随访2年）。确诊后2年至10年的总生存率介于90%至70%之间。医源性KS患者死亡率较高（52.9%）。本研究反映了我们在KS诊疗中的实践经验。患者常合并多种并发症，治疗方案呈现多样性。在诊断、治疗及随访过程中，由多学科转诊专家组成的协作模式对本病的规范管理至关重要。
肿瘤(癌症)患者之家